Get started
Author

Allison M. Booth

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
2018 · Jennifer A. Woyach, Amy S. Ruppert, et al. · New England Journal of Medicine · 962
PDF
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
2021 · Jennifer A. Woyach, Amy S. Ruppert, et al. · Blood · 57
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202
2018 · Jennifer A. Woyach, Amy S. Ruppert, et al. · Blood · 19
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
2021 · Amy S. Ruppert, Allison M. Booth, et al. · Leukemia · 16
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
2019 · Jennifer Woyach, Amy S. Ruppert, et al. · Blood · 6
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia
2021 · Matthew C. Cheung, Nicole Mittmann, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502
2010 · Eyal C Attar, Kathleen A. Donohue, et al. · Blood · 5
A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
2021 · Jennifer A. Woyach, Amy S. Ruppert, et al. · Blood · 4
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials
2026 · Allison Booth, Shauna Hillman, et al. · Journal of Thoracic Oncology · 3
Beyond the Basics: Advanced REPORT Procedure Tips and Tricks Updated for SAS ® 9.2
2011 · Allison M. Booth · 2
A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia
2020 · Matthew C. Cheung, Nicole Mittmann, et al. · Blood · 1
Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.
2020 · Amy S. Ruppert, Sumithra J. Mandrekar, et al. · Journal of Clinical Oncology
Works count: 12
Citation count: 1,080
H-index: 5
I10-index: 4
Year
Topic
Type